Home Biosciences is a new breed of biotech, leveraging an asset-centric operating model.
Home Biosciences is the partner of choice for academics and scientists to transform their ideas into life changing therapies for patients. Every step f the way, Home Biosciences works together with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. Each project is is housed in a dedicated entity (SPV), fully financed by Home Biosciences and led by teams focused on the day-to-day execution of its projects with oversight from the Home Biosciences management team.
Home Biosciences’ stage-gated approach accelerates and “de-risks” discovery and development path, while enabling quick decision-making.
Identify – Build – Grow
We work with academics and scientists on ground-breaking projects addressing unmet medical needs
We bring together talented, highly skilled execution teams and leverage innovative R&D approaches to maximize project outcomes.
We accelerate the discovery and development path thanks to rigorous processes, while making sure the interests of all parties are aligned
Focus – Execute
We assemble dedicated project teams that are empowered and accountable for day-to-day execution
We oversee execution to ensure that projects move forward on time
We provide funding and operational support to allow full focus of the project teams
One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat diseases. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Insitut Curie.
More to come
Magali has fifteen years of experience in the field of biotechnology, combining academia and industry. Magali graduated from Ecole Polytechnique and Ecole des Mines de Paris, and holds a PhD in Molecular Biology (Paris 6). From 2009 to 2011 she was Scientist at Biomarin, pursuing in the rare diseases space and gaining biotech experience in the United States. Subsequently, Magali spent 6 years at the Boston Consulting Group (2011-2016), member of the Healthcare practice within the Paris office, working with various large pharmaceutical companies on all activities along the value chain, as well as biotech companies and investors around new value creation models for emerging technologies. She then joined the Executive Committee of DBV Technologies as Chief Strategy Officer between 2016 and 2019, in charge of continuing the transformation from a biotech R&D company into an integrated pharmaceutical company.
David has more than twenty years of professional experience, mainly in the pharmaceutical and biotechnology industry. From 2011 to 2020, he co-headed DBV Technologies, transforming the company from a French research start-up to an unicorn about to launch a treatment of primary importance in the United States. During this period, he led two IPOs on Euronext and Nasdaq, raising around one billion US dollars in total. David began his career as an investment banker in mergers & acquisitions at Warburg Dillon Read, before joining Technicolor, a CAC40 double-listed company on NYSE and Euronext, as head of financial communication. He then worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group Chief Financial Officer, before moving to DBV. David graduated from Paris Dauphine and Imperial College (London).
Dr. Michel Vellard has more than 20 years of experience in the pharmaceutical industry and has been part of the beginning, growth and success of several companies. Previously, Michel was Vice President of Research at Ultragenyx from 2013 to 2018. Before this, he worked at BioMarin Pharmaceutical Inc., from 1999 as Head of Lysosomal Biology, where he directed research on rare diseases. Prior to BioMarin, Michel did a post-doc training at UCLA, where he focused on cystinosis, a rare lysosomal genetic disease. In 1992, Dr. Vellard completed his Ph.D. in Microbiology at the Pasteur and the Curie Institutes in Paris (France) on the regulation of the transcription of the proto-oncogene c-myb. Michel’s work on genetics, molecular biology and particularly on treatments of rare diseases has been recognized by several prestigious awards, numerous patents and more importantly 9 approvals, so far.
David Schilansky, Chairman & CEO
Magali Richard, deputy CEO
Ming Fang, Managing Director, Redmile Group
Antoine Papiernik, Managing Partner, Sofinnova Partners
